Citations

Clear

181 citation(s) found for "Good, J".

Prognostic Model for Progression of Autosomal Dominant Polycystic Kidney Disease to Kidney Failure
Cohen, Aarón , Landsittel, Douglas , Chapman, Arlene B., Mrug, Michal , Bae, Kyongtae T., Yu, Alan S.L. , Ables, Erin , Torres, Vicente E. , Chebib, Fouad T. , Harris, Peter C. , Rahbari-Oskoui, Frederic F. , Dickinson, Stephanie , Bennett, William M. , Landsittel, Douglas P.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 209-209

10.1681/asn.20233411s1209c Get It

Volume Progression and Imaging Classification of Polycystic Liver in ADPKD
Bae, Kyongtae T., Tao, Cheng , Feldman, Robert , Chapman, Arlene B., Brosnahan, Godela , Steinman, Theodore I., Braun, William E. , Mrug, Michal , Landsittel, Douglas , Yu, Alan S.L. , Torres, Vicente E. , Perrone, Ronald D. , Bennett, William M. , Harris, Peter C. , Abebe, Kaleab Z

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 500-500

10.1681/asn.20203110s1500c Get It

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Mezzanotte-Sharpe, Jessica , O’Neill, Anne, Arteaga, Carlos L. , Yang, Ximing J. , Cella, David , Meropol, Neal J. , Alpaugh, R. Katherine , Saphner, Thomas J. , Swaney, Robert E., Hoelzer, Karen L., Gradishar, William J. , Sundaram, P. Kothai, Jilani, Shamim Z., Perez, Edith A. , Jahanzeb, Mohammad , Reid, Sonya , Mayer, Ingrid A. , Wagner, Lynne I. , Abramson, Vandana G. , Lin, Nancy U. , Wolff, Antonio C. , Sledge, George W.

Mayo Clinic

No container title available | April 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4295044/v1 | PMID 38746356 Get It

Abstract Background In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical and preliminary clinical activity of the trastuzumab and bevacizumab combination, ECOG-ACRIN E1105 trial was developed to determine if the addition of bevacizumab to a chemotherapy and trastuzumab combination for first-line therapy would improve progression-free survival (PFS) in patients with HER2-positive MBC. Findings: 96 patients were randomized to receive standard first-line chemotherapy and trastuzumab with or without bevacizumab between November 2007 and October 2009, and 93 began protocol therapy. Induction therapy was given for 24 weeks, followed by maintenance trastuzumab with or without bevacizumab. 60% (56/93) began carboplatin and 74% (69/93) completed 6 cycles of induction therapy. Primary endpoint was PFS. Median PFS was 11.1 and 13.8 months for placebo and bevacizumab arms, respectively (hazard ratio [HR] 95%, Confidence Interval [Cl] for bevacizumab vs. placebo: 0.73 [0.43–1.23], p = 0.24), and at a median follow-up of 70.7 months, median survival was 49.1 and 63 months (HR [95% Cl] for OS: 1.09 [0.61–1.97], p = 0.75). The most common toxicities across both arms were neutropenia and hypertension, with left ventricular systolic dysfunction, fatigue, and sensory neuropathy reported more frequently with bevacizumab. Conclusions In this trial, the addition of bevacizumab did not improve outcomes in patients with metastatic HER2-positive breast cancer. Although the trial was underpowered due to smaller than anticipated sample size, these findings corroborated other clinical trials during this time.
Using Curiosity, in Good Faith, as a Marker of an Exceptional Clinician
Abdelwahab, Rewan , Abdelwahab, Rewan M

Mayo Clinic

Academic Medicine | March 25, 2024 | Volume: 99 | Issue: 6 | Pages: e1-e2

10.1097/acm.0000000000005716 | PMID 38526952 Get It

Partnering With Parents to Dismantle “Good-Death” Narratives
McCarthy, Sarah , Snaman, Jennifer M. , McCarthy, Sarah R. , McCarthy, Sarah R , Broden, Elizabeth G. , McCarthy, Sarah R.

Mayo Clinic

JAMA Pediatrics | March 11, 2024 | Volume: 178 | Issue: 5 | Pages: 431

10.1001/jamapediatrics.2024.0103 | PMID 38466276 Get It

This Viewpoint dismantles the notion of a “good death” in pediatrics using quotes from bereaved parents and provides actionable alternatives to improve quality end-of-life care for dying children and their families.
Defining the Role of the Advanced Practice Provider Within the National Cancer Institute Community Oncology Research Program
Braun‐Inglis, Christa , Dressler, Emily V. , Myers, Jamie , Benson, Al B. , Flannery, Marie , Good, Marjorie J. , Denicoff, Andrea , Berenberg, Jeffrey L. , DeTroye, Alisha , O'Brien, Bridget, Kottschade, Lisa A. , Omatsu, Dee Ann, Foust, Melyssa , Lesser, Glenn J. , Braun-Inglis, Christa M , Myers, Jamie S , Good, Marjorie , Kottschade, Lisa A , Nightingale, Chandylen L , Dressler, Emily V , Kittel, Carol , Nightingale, Chandylen L.

Mayo Clinic

JCO Oncology Practice | January 4, 2024 | Volume: 20 | Issue: 2 | Pages: 239-246

10.1200/op.23.00501 | PMID 38175992 Get It

PURPOSE Oncology advanced practice providers (APPs), including nurse practitioners, clinical nurse specialists, physician assistants, and clinical pharmacists, contribute significantly to quality cancer care. Understanding the research-related roles of APPs in the National Cancer Institute's (NCI) Community Oncology Research Program (NCORP) could lead to enhanced protocol development, trial conduct, and accrual. METHODS The 2022 NCORP Landscape Assessment Survey asked two questions about the utilization and roles of APPs in the NCORP. RESULTS A total of 271 practice groups completed the 2022 survey, with a response rate of 90%. Of the 259 nonpediatric exclusive practice groups analyzed in this study, 92% used APPs for clinical care activities and 73% used APPs for research activities. APPs most often provided clinical care for patients enrolled in trials (97%), followed by assistance with coordination (65%), presenting/explaining clinical trials (59%), screening patients (49%), ordering investigational drugs (37%), and consenting participants (24%). Some groups reported APPs as an enrolling investigator (18%) and/or participating in institutional oversight/selection of trials (15%). Only 5% of NCORP sites reported APPs as a site primary investigator for trials, and very few (3%) reported APPs participating in protocol development. CONCLUSION Practice groups report involving APPs in clinical research within the NCORP network; however, opportunities for growth exists. As team-based care has enhanced clinical practice in oncology, this same approach can be used to enhance successful research. Suggested strategies include supporting APP research-related time, recognition, and education. The findings of this survey and subsequent recommendations may be applied to all adult oncology practices that participate in clinical research.
Abstract 305: Practice How You Play! An Innovative Two-Pronged Approach at Improving Resident and Allied Health Staff Performance During Code Blue Events
Fatunde, Olubadewa A. , Odneal, John, Schwind, Valarie, Egbe, Tiffany, Kirbow, Karin, Muddana, Prithvi, Neidlinger, Beth A, Stokes, Michelle, Wright, Belinda, Stokes, Michelle

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.305 Get It

Introduction/Background: Cardiopulmonary arrest (Code Blue or CB) is a feared complication of severe medical illnesses. In-hospital CB events (CBE) have been estimated to have a mortality rate of only 30.4%. CBEsare difficult to prepare for and execute due many factors, including their low frequency, high complexity, and unpredictability. Research Questions/Hypothesis: Over 6 months (March - September 2019), we tested the effects of both adaptation of a Code Blue (CB) Team Leader (TL) checklist—aimed at improving resident leadership and communication—as well as implementation of an interdisciplinary in-hospital CB simulation to improve the performance of both resident physicians. Methods/Approach: Primary outcomes included change in resident confidence leading a CBE (i.e. Level of comfort as TL , confidence of diagnosis and management, confidence in code-related procedural skills), and familiarity with the institutional rapid response protocol. Secondary outcomes included self-reported confidence of nurses to execute their role, and both physician and nurse time to response. Confidence parameters were measured by a 10 point Likert scale. Pre-intervention, baseline cross-sectional survey values of the primary outcome were obtained from 24 internal medicine residents (12 PGY2s, 12 PGY3) over 6 months. Post-intervention, the cross-sectional survey was repeated. Results/Data (descriptive and inferential statistics): Statistics for residents displayed in table and figure 1. The level of nurse confidence increased from 7.5 to 8.25 over 5 months. The time to first response by residents has decreased by more than 50%. Conclusion(s) Our project improved the quality and resident level of comfort running Code Blue events among both residents and nurses.
552: THE IMPACT OF THE COVID-19 PANDEMIC ON MRSA PNEUMONIA ADMISSIONS: A NATIONAL INPATIENT STUDY
Labban, Mohamad El , Aboelnasr, Amr, Vo, Natasha, Olorode, Gbemisola, Niaz, Fayreal, Khan, Syed Anjum , Chaaban, Toufic , Wahab, Abdul

Mayo Clinic

Critical Care Medicine | December 14, 2023 | Volume: 52 | Issue: 1 | Pages: S249-S249

10.1097/01.ccm.0001000384.11380.59 Get It

Gowers and Osler: Good Friends “All Through” (P2.401)
Boes, Christopher J.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p2.401 Get It

Thermodynamic Indices of Brain Activity to Identify People with Good Cognitive Capacity (P4-6.002)
Shivabalan, K R, Byale, Anjali , Ajith, Karthik, Yadav, Devvrat , Mishra, Rahul , Gautam, Misha

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1521 Get It